Metastasis, Stomach Neoplasms
Conditions
Keywords
Diagnosis
Brief summary
To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and hematogenous metastasis of advanced gastric cancer; To explore the influence of the number and type of CTCs and ctDNA on metastasis and prognosis.
Interventions
DIAGNOSTIC_TESTCTC test
Circulating tumor cells test of ascites and blood for patients with gastric cancer.
DIAGNOSTIC_TESTctDNA test
Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
Sponsors
First Hospital of China Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who sign informed consent. 2. Gastric cancer is determined by more than 2 pathologists. 3. Patients with Borrmann III/IV gastric cancer.
Exclusion criteria
1. Patients who complicate with other malignant tumors. 2. Patients who complicate with other serious heart and lung diseases. 3. Patients who receive preoperative neoadjuvant chemotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantity of CTCs | 1 day | To count the circulating tumor cells in ascites and blood. |
| Classification of CTCs | 1 day | To classify the circulating tumor cells in ascites and blood. |
| Expression of ctDNA | 1 day | To assess the expression of circulating tumor DNA in ascites and blood, including YAP1, LAMC1 and DDIT4. |
Countries
China
Contacts
Primary ContactKai Li, MD
Outcome results
None listed